MX2021008525A - Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia. - Google Patents
Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia.Info
- Publication number
- MX2021008525A MX2021008525A MX2021008525A MX2021008525A MX2021008525A MX 2021008525 A MX2021008525 A MX 2021008525A MX 2021008525 A MX2021008525 A MX 2021008525A MX 2021008525 A MX2021008525 A MX 2021008525A MX 2021008525 A MX2021008525 A MX 2021008525A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- interleukin
- therapy
- mutated
- cytokine
- Prior art date
Links
- 102100033499 Interleukin-34 Human genes 0.000 title abstract 5
- 101710181549 Interleukin-34 Proteins 0.000 title abstract 5
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 230000007512 neuronal protection Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2334—Interleukin-34 (IL-34)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
Abstract
La interleucina-34 es una citocina que participa en la diferenciación y supervivencia de macrófagos, monocitos y células dendríticas en respuesta a la inflamación. La participación de IL-34 se ha mostrado en áreas tan diversas como protección neuronal, enfermedades autoinmunes, infecciones, cáncer y trasplantes. Un trabajo reciente también ha demostrado un nuevo y posible papel terapéutico para la IL-34 como mediador de la tolerancia al trasplante de citocinas secretadas por Treg Foxp3+. Los inventores generaron ahora nuevos polipéptidos de IL-34 mutados que pueden utilizarse como agonistas o antagonistas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19305046 | 2019-01-15 | ||
PCT/EP2020/050920 WO2020148338A1 (en) | 2019-01-15 | 2020-01-15 | Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021008525A true MX2021008525A (es) | 2021-11-12 |
Family
ID=65228484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021008525A MX2021008525A (es) | 2019-01-15 | 2020-01-15 | Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220098264A1 (es) |
EP (1) | EP3911670A1 (es) |
JP (1) | JP2022517029A (es) |
KR (1) | KR20210121077A (es) |
CN (1) | CN113508129A (es) |
AU (1) | AU2020208909A1 (es) |
BR (1) | BR112021013944A8 (es) |
CA (1) | CA3126741A1 (es) |
IL (1) | IL284868A (es) |
MX (1) | MX2021008525A (es) |
SG (1) | SG11202107606VA (es) |
WO (1) | WO2020148338A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115819614B (zh) * | 2022-06-21 | 2024-02-23 | 四川大学华西医院 | 一种基于il34的嵌合抗原受体免疫细胞制备及其应用 |
WO2023246908A1 (zh) * | 2022-06-21 | 2023-12-28 | 四川大学华西医院 | 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR520E (fr) | 1901-11-13 | 1903-01-26 | Bermont Victor Etienne | Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5) |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
EP0465529B1 (en) | 1989-03-21 | 1998-04-29 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
EP0753069A1 (en) | 1994-04-15 | 1997-01-15 | Targeted Genetics Corporation | Gene delivery fusion proteins |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | 免疫療法のctla−4結合ペプチド |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
KR100849443B1 (ko) | 1998-12-23 | 2008-07-31 | 화이자 인크. | Ctla-4에 대한 인간 단일클론 항체 |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート,エルエルシー | Ctla4(cd152)に対する抗体、これを含む結合体、およびその使用 |
DE60135029D1 (de) | 2000-07-03 | 2008-09-04 | Bristol Myers Squibb Co | Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis |
EP2116228A1 (en) | 2001-10-19 | 2009-11-11 | Isotechnika Inc. | Novel cyclosporin analog microemulsion preconcentrates |
NZ581541A (en) | 2002-10-17 | 2011-07-29 | Genmab As | Human monoclonal antibodies against CD20 |
CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
EP2287310B1 (en) * | 2004-07-22 | 2015-05-06 | Five Prime Therapeutics, Inc. | Compositions and methods using MGD-CSF in disease treatment |
PL2439273T3 (pl) | 2005-05-09 | 2019-08-30 | Ono Pharmaceutical Co., Ltd. | Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami |
RS54271B1 (en) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1) |
TW200738261A (en) | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
HUE034465T2 (en) | 2008-02-11 | 2018-02-28 | Cure Tech Ltd | Monoclonal antibodies for tumor treatment |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
MX2011002252A (es) | 2008-08-25 | 2011-06-24 | Amplimmune Inc | Composiciones de antagonistas del pd-1 y metodos de uso. |
KR20110074850A (ko) | 2008-08-25 | 2011-07-04 | 앰플리뮨, 인크. | Pd-1 길항제 및 그의 사용 방법 |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
JP5748653B2 (ja) | 2009-04-10 | 2015-07-15 | 協和発酵キリン株式会社 | 抗tim−3抗体を用いた血液腫瘍治療法 |
US8289808B2 (en) | 2009-04-16 | 2012-10-16 | Chevron U.S.A., Inc. | System and method to estimate compressional to shear velocity (VP/VS) ratio in a region remote from a borehole |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
CN103079644B (zh) | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
CN103987405B (zh) | 2011-11-28 | 2017-03-29 | 默克专利股份公司 | 抗pd‑l1抗体及其用途 |
KR20150128891A (ko) | 2013-03-15 | 2015-11-18 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제 (ido)의 억제제 |
AU2014316682B2 (en) | 2013-09-06 | 2018-11-22 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
SI3041828T1 (sl) | 2013-09-06 | 2018-10-30 | Aurigene Discovery Technologies Limited | 1,3,4-oksadiazolni in 1,3,4-tiadiazolni derivati kot imunomodulatorji |
EP3169350B1 (en) * | 2014-07-17 | 2019-01-09 | INSERM - Institut National de la Santé et de la Recherche Médicale | An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases |
CN106084030B (zh) * | 2016-04-25 | 2019-11-08 | 北京大学 | 一种提高白细胞介素il-34热稳定性的方法 |
-
2020
- 2020-01-15 CN CN202080017907.2A patent/CN113508129A/zh active Pending
- 2020-01-15 JP JP2021540589A patent/JP2022517029A/ja active Pending
- 2020-01-15 SG SG11202107606VA patent/SG11202107606VA/en unknown
- 2020-01-15 BR BR112021013944A patent/BR112021013944A8/pt unknown
- 2020-01-15 KR KR1020217024902A patent/KR20210121077A/ko unknown
- 2020-01-15 US US17/422,556 patent/US20220098264A1/en active Pending
- 2020-01-15 MX MX2021008525A patent/MX2021008525A/es unknown
- 2020-01-15 AU AU2020208909A patent/AU2020208909A1/en active Pending
- 2020-01-15 WO PCT/EP2020/050920 patent/WO2020148338A1/en unknown
- 2020-01-15 CA CA3126741A patent/CA3126741A1/en active Pending
- 2020-01-15 EP EP20700307.0A patent/EP3911670A1/en active Pending
-
2021
- 2021-07-14 IL IL284868A patent/IL284868A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021013944A8 (pt) | 2021-12-21 |
JP2022517029A (ja) | 2022-03-03 |
EP3911670A1 (en) | 2021-11-24 |
KR20210121077A (ko) | 2021-10-07 |
SG11202107606VA (en) | 2021-08-30 |
CA3126741A1 (en) | 2020-07-23 |
IL284868A (en) | 2021-08-31 |
AU2020208909A1 (en) | 2021-07-29 |
US20220098264A1 (en) | 2022-03-31 |
WO2020148338A1 (en) | 2020-07-23 |
CN113508129A (zh) | 2021-10-15 |
BR112021013944A2 (es) | 2021-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021008525A (es) | Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia. | |
TWD217252S (zh) | 充電器 | |
MX2022001018A (es) | Electrodos metalicos de bajo costo. | |
MX2022005404A (es) | Compuestos de fijación a il-2r e il-7r dual. | |
PH12020551026A1 (en) | Fusion protein comprising il-2 protein and cd80 protein, and use thereof | |
BRPI0721259B8 (pt) | composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto | |
IN266744B (es) | ||
TWD210683S (zh) | 電池 | |
EP3980035A4 (en) | GENETICALLY MODIFIED CD4+ T LYMPHOCYTES FOR USE IN TREG-BASED IMMUNOTHERAPY | |
MX2018006462A (es) | Chaleco de miembro de la tripulacion ferroviaria para uso dentro de un patio de ferrocarriles. | |
TWD206953S (zh) | 果汁機之底座 | |
WO2018222379A3 (en) | SOLID STATE LITHIUM-METAL BATTERY BASED ON THREE-DIMENSIONAL ELECTRODE DESIGN | |
WO2020187340A3 (es) | Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva | |
MX2021004916A (es) | Nuevas composiciones proteicas de diseño idóneo. | |
CN204019279U (zh) | 一种转盘式双端面磨床 | |
WO2019045805A3 (en) | PROCESS FOR METALLIZING ELECTROCHEMICALLY ACTIVE POWDERS | |
CN206211399U (zh) | 一种闭式卡具 | |
WO2022261455A3 (en) | Genetically-modified saccharomyces yeast strains as preventative and therapeutic agents | |
WO2021178833A3 (en) | Designed il-2 variants | |
CN208514093U (zh) | 一种cnc工作台模具钢材校正装置 | |
WO2021020884A3 (ko) | 사이토신 염기교정용 조성물 및 이의 용도 | |
CN203817406U (zh) | 相机连接环上下料机构及相机连接环自动加工设备 | |
FR3024842B1 (fr) | Dispositif pour l'usinage electrochimique de pieces metalliques | |
MX2021007853A (es) | Compuestos de tienopiridinona. | |
WO2019054809A3 (ko) | 자가면역질환 및 골질환 치료제로서의 펩타이드의 용도 |